SPD 502 (NS 1209), a New Selective AMPA Antagonist, Reduces the Infarct Size in Rats Following Permanent Occlusion of the Middle Cerebral Artery
Alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate (AMPA)-antagonists (i.e., 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline [NBQX] and 6-(1-imidazolyl)-7-nitroquinoxaline-2,3(1H,4H)-dione [YM900]) have shown protective effects in different animal models of focal and global cerebral ischemia. We have developed a new highly selective and water-soluble AMPA antagonist (SPD 502). The compound is well-tolerated in rodents producing no liver or kidney pathology after doses up to 120 mg/kg. The aim of the present study was to evaluate whether SPD 502 was also neuroprotective in a focal cerebral ischemia model.